Active Awards Portfolio Dashboard

It takes a lot of effort to develop a promising stem cell research idea into an effective treatment that can help patients. CIRM funds a pipeline of projects spanning discovery, translation and clinical stage research. Check out our portfolio of active research awards in our interactive dashboard below. For a detailed list of CIRM-funded clinical trials, visit our Clinical Trials Dashboard.

Filter Awards

Disease Cell Type Therapeutic or Technologysort descending Institution Stage Project Objective Details
Ovarian Cancer Adult Stem Cell Gene-modified, donor cell therapy COH
Pre-IND/IDE or Equivalent
COVID-19 Adult Stem Cell Gene-modified, donor cell therapy COH
Development Candidate, Proof of Concept
Ovarian Cancer iPS Cell Gene-modified, donor cell therapy UCSD
Development Candidate, Proof of Concept
Cancer Adult Stem Cell Gene-modified, donor cell therapy UCLA
Development Candidate, Proof of Concept
Amyotrophic Lateral Sclerosis Adult Stem Cell Gene-modified, donor cell therapy Cedars-Sinai
Clinical Trial, Phase 1 or Phase 1/2
Type 1 diabetes Embryonic Stem Cell Gene-modified, donor cell therapy Lundquist Institute
Development Candidate, Proof of Concept
Liver Disease iPS Cell Gene-modified, donor cell therapy CHLA
Development Candidate, Proof of Concept
COVID-19,
Respiratory Disorders
iPS Cell Gene-modified, donor cell therapy USC
Development Candidate, Proof of Concept
Blood Cancer Adult Stem Cell Gene-modified, donor cell therapy Angiocrine
Clinical Trial, Phase 1 or Phase 1/2
COVID-19 Embryonic Stem Cell,
iPS Cell
Gene-modified, donor cell therapy COH
Proof of Concept
COVID-19 Adult Stem Cell Gene-modified, donor cell therapy UCLA
Development Candidate, Proof of Concept
Parkinson's Disease Adult Stem Cell Gene-modified, donor cell therapy UCSF
IND
Sickle Cell Disease Adult Stem Cell Gene-modified, personalized cell therapy UCSF
IND
Hyper IgM Syndrome,
Immune Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Pre-IND/IDE or Equivalent
Heart Disease,
Danon Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCSD
Development Candidate, Proof of Concept
Sarcoma Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Clinical Trial, Phase 1 or Phase 1/2
Immune Disease,
Leukocyte Adhesion Deficiency
Adult Stem Cell Gene-modified, personalized cell therapy Rocket Pharmaceuticals, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Blood Disorders Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Development Candidate, Proof of Concept
Immune Disease,
Severe Combined Immunodeficiency, X-linked (X-SCID)
Adult Stem Cell Gene-modified, personalized cell therapy St. Jude
Clinical Trial, Phase 1 or Phase 1/2
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) Adult Stem Cell Gene-modified, personalized cell therapy UCSF
Clinical Trial, Phase 1 or Phase 1/2
Cystinosis,
Kidney Failure
Adult Stem Cell Gene-modified, personalized cell therapy UCSD
Clinical Trial, Phase 1 or Phase 1/2
Sickle Cell Disease Adult Stem Cell Gene-modified, personalized cell therapy UCSF
Pre-IND/IDE or Equivalent
Sickle Cell Disease Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Clinical Trial, Phase 1 or Phase 1/2
B cell cancers,
Leukemia
Adult Stem Cell Gene-modified, personalized cell therapy Stanford
Clinical Trial, Phase 1 or Phase 1/2
Beta Thalassemia Adult Stem Cell Gene-modified, personalized cell therapy Sangamo
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer,
Breast Cancer
Adult Stem Cell Gene-modified, personalized cell therapy COH
Clinical Trial, Phase 1 or Phase 1/2
Leukemia Cancer Stem Cell Gene-modified, personalized cell therapy UCSD
Pre-IND/IDE or Equivalent
Immune Disease,
Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)
Adult Stem Cell Gene-modified, personalized cell therapy Orchard Therapeutics
Clinical Trial, Phase 2
Lung Cancer Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Clinical Trial, Phase 1 or Phase 1/2
HIV/AIDS Adult Stem Cell Gene-modified, personalized cell therapy COH
Clinical Trial, Phase 1 or Phase 1/2
HIV-related Lymphoma,
HIV/AIDS
Adult Stem Cell Gene-modified, personalized cell therapy UC Davis
Clinical Trial, Phase 1 or Phase 1/2
Leukemia, Acute Myeloid (AML) Cancer Stem Cell Gene-modified, personalized cell therapy UCSF
Pre-IND/IDE or Equivalent
Immune Disease,
X-linked Chronic Granulomatous Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Clinical Trial, Phase 1 or Phase 1/2
Sickle Cell Disease Adult Stem Cell Gene-modified, personalized cell therapy Boston Children's Hospital
Clinical Trial, Phase 2
Brain Cancer Adult Stem Cell Gene-modified, personalized cell therapy COH
Clinical Trial, Phase 1 or Phase 1/2
Canavan Disease iPS Cell Gene-modified, personalized cell therapy COH
Pre-IND/IDE or Equivalent
Brain Cancer Adult Stem Cell Gene-modified, personalized cell therapy COH
IND
Leukemia, Acute Myeloid (AML),
Multiple Myeloma
Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Pre-IND/IDE or Equivalent
Multiple Myeloma Adult Stem Cell Gene-modified, personalized cell therapy Poseida Therapeutics
Clinical Trial, Phase 1 or Phase 1/2
Brain Cancer Adult Stem Cell Gene-modified, personalized cell therapy UCSF
Development Candidate, Proof of Concept
Blood Disorders,
Immune Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCLA
Proof of Concept
HIV/AIDS,
Immune Disease
Adult Stem Cell Gene-modified, personalized cell therapy UCSF
Clinical Trial, Phase 1 or Phase 1/2
Epidermolysis Bullosa iPS Cell Gene-modified, personalized cell therapy Stanford
Pre-IND/IDE or Equivalent
Ovarian Cancer Adult Stem Cell Gene-modified, personalized cell therapy COH
Development Candidate, Proof of Concept
Bone or Cartilage Disease Adult Stem Cell Gene-modified, personalized cell therapy Rocket Pharmaceuticals, Inc.
Clinical Trial, Phase 1 or Phase 1/2
Hearing Loss iPS Cell Model system development USC
Proof of Concept, Tool/Resources/Bottleneck
COVID-19,
Respiratory Disorders
Adult Stem Cell Model system development UCLA
Development Candidate, Proof of Concept, Tool/Resources/Bottleneck
COVID-19 iPS Cell Model system development UC Berkeley
Proof of Concept
Amyotrophic Lateral Sclerosis iPS Cell Nucleic acid based therapy USC
Development Candidate, Proof of Concept
Multiple Myeloma Adult Stem Cell Personalized cell therapy UCLA
Pre-IND/IDE or Equivalent

Pages

Icon for csv export